STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #235 by analyst upside · 2026-06-27
PALI
Palisade Bio, Inc.
Healthcare · Market Cap $328M · P/E 15.8x
ANALYST PRICE TARGET
+414.0%
implied upside to consensus target
Current Price $1.89
Consensus Target $9.71
Bull Target $25.0
Bear Target $5.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
5
Hold
0
Sell
0
52-Week Low $0.53
52-Week High $2.86
YTD Return -24.4%
FUNDAMENTALS
Market Cap $328M
P/E Ratio (TTM) 15.8x
Forward P/E -6.6x
EPS (TTM) $0.12
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.53
52-Week High $2.86
Current Price $1.89
Bear Target $5.0
Bull Target $25.0
● Now $1.89 ● Target $9.71
TRADING DATA
Avg Volume 3.6M
YTD Return -24.4%
Analyst Count 7
Consensus Buy
Upside to Target +414.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Palisade Bio, Inc. (PALI) is currently trading at $1.89 with a Wall Street consensus price target of $9.71, implying potential upside of 414.0% over the next 12 months. 7 analysts currently cover PALI, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $25.0, while the most cautious has a target of $5.0.

PALI operates in the Healthcare sector with a market capitalisation of $328M. The stock is down 24.4% year-to-date and is currently trading near the upper end of its 52-week range of $0.53 – $2.86.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PALI, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wolfe Research ● Initiated
Outperform 2026-04-09 Building track record
HC Wainwright & Co. ● Initiated
Buy 2026-03-26 31% win rate (48 calls)
Stifel ● Initiated
Buy 2026-02-25 Building track record
B. Riley Securities ● Initiated
Buy 2026-01-09 17% win rate (6 calls)
Clear Street ● Initiated
Buy 2025-12-30 Building track record
Piper Sandler ● Initiated
Overweight 2025-12-29 14% win rate (7 calls)
Brookline Capital — Reiterated
Buy → Buy 2025-05-13 20% win rate (5 calls)
Brookline Capital ● Initiated
Buy 2024-11-20 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
16/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →